Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine
COPENHAGEN, Denmark, June 29, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that Health Canada has approved VIMKUNYA® (recombinant, adsorbed) for immunization to prevent disease caused by chikungunya virus infection for individuals 12 years of age and older.
COPENHAGEN, Denmark, June 29, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that Health Canada has approved VIMKUNYA® (recombinant, adsorbed) for immunization to prevent disease caused by chikungunya virus infection for individuals 12 years of age and older.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.